Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

@article{Hammond2010HumanIV,
  title={Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.},
  author={Emma L Hammond and E. Edwards McKinnon and David N Nolan},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2010},
  volume={51 5},
  pages={591-9}
}
BACKGROUND Lipoatrophy and metabolic complications of treatment of human immunodeficiency virus (HIV) infection may share common associations with adipose tissue pathology and inflammation. To investigate these relationships, we undertook a large-scale study of adipose tissue, body composition, and metabolic outcomes among HIV-infected adult men at a tertiary hospital HIV cohort during the period 2001-2007. METHODS Assessments included adipose biopsies (n = 211) for investigation of adipocyte… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

ABCDE Study Team. How much fat loss is needed for lipoatrophy to become clinically evident

  • D Podzamczer, E Ferrer, E Martı́nez
  • AIDS Res Hum Retroviruses
  • 2009
1 Excerpt

MEDICLAS study group. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss

  • MG van Vonderen, MA van Agtmael, EA Hassink
  • PLoS One
  • 2009

Similar Papers

Loading similar papers…